Furthermore, loss of DEAR1 expression correlated significantly with loss of progesterone receptor expression and with the triple-negative phenotype (ER−, PR−, HER-2−) of breast cancers (r = 0.21, p = 0.0362), a subgroup common in BRCA1 mutation carriers and identified by gene expression profiling as breast cancers of poor prognosis and for which few treatment options exist (Table 1) [40]. This evidence concerns the gene ERBB2 and breast carcinoma.